Psychedelic Bulletin: COMPASS’ “Infamous” Psilocybin Patent Challenged; atai Stock Price Tumbles As Lock-Up Expiry Date Arrives; UT Austin Launches Psychedelics Centre Post published:December 17, 2021 Post category:Psychedelic Bulletin
MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias Post published:December 17, 2021 Post category:Press Release
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD Post published:December 17, 2021 Post category:Press Release
COMPASS Selected for Addition to NASDAQ Biotechnology Index Post published:December 17, 2021 Post category:Press Release
Psyched Wellness Announces Path to Market for AME-1-derived Products in the USA Post published:December 16, 2021 Post category:Press Release
COMPASS Pathways announces changes in Executive Team Post published:December 16, 2021 Post category:Press Release
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022 Post published:December 16, 2021 Post category:Press Release
Entheon Biomedical Announces EEG Patent Application & Provides Research Update Post published:December 16, 2021 Post category:Press Release
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospitalās Center for the Neuroscience of Psychedelics Post published:December 16, 2021 Post category:Press Release
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights Post published:December 15, 2021 Post category:Press Release